Clinical Trial Update: A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy. [Phase 1]

View source ↗

Summary

Phase 1 study evaluating siremadlin with venetoclax and azacitidine in adults with acute myeloid leukemia ineligible for chemotherapy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Siremadlin (siremadlin)
• VIDAZA (AZACITIDINE)
• Venclexta (venetoclax)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: TERMINATED